Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL

This study aims to investigate a novel therapeutic strategy of integrated radiotherapy before autologous stem cell transplantation (ASCT) sequential chimeric antigen receptor T-cell(CAR-T) therapy for patients with relapsed/refractory(R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL). By evaluating the efficacy and safety of this multimodal approach, we seek to provide a theoretical foundation and clinical data to optimize outcomes for relapsed/refractory aggressive B-NHL patients.

NCT Number	NCT07059741
Lead Sponsor	The First Affiliated Hospital of Soochow University
Conditions	Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
Enrollment	20 participants
Start Date	2024-12-10
Primary Completion	2028-12-10 (estimated)
Study Completion	2028-12-10 (estimated)
Updated on ClinicalTrials.gov	2025-07-11